ACCESS Newswire

NLS Pharmaceutics AG

Share
NLS Pharmaceutics Announces Launch of Paid for Named Patient Program with Mazindol ER for Idiopathic Hypersomnia, a Serious Sleep Disorder with No Approved Treatment Options in Europe

ZURICH, SWITZERLAND / ACCESSWIRE / November 23, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP), (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that it has launched a paid for Named Patient Program (NPP) for patients suffering from idiopathic hypersomnia (IH). NLS has partnered with Caligor Coghlan Pharma Services, a globally active pharmaceutical company specializing in named patient, expanded access, early access and compassionate use programs. The NPP will provide access to Mazindol ER for the treatment of IH where this medication would not otherwise be available for this indication in certain countries. The NPP for IH was launched in the United Kingdom this week and is expected to expand into other countries over the coming weeks and months.

"After months of preparation we are excited to launch a NPP for people living with idiopathic hypersomnia who currently have no approved treatment options. We are deeply grateful to the regulatory bodies as well as medical experts who facilitate new therapies for IH, and look forward to working quickly to make Mazindol ER available to patients under this program as soon as possible", said Alex Zwyer, Chief Executive Officer of NLS.

IH is a chronic, neurological disorder that is characterized by excessive sleepiness, an uncontrollable need to sleep or daytime sleepiness that persists for at least three months even with adequate or prolonged night-time sleep. IH affects approximately three in 10,000 people in the European Union (EU). This is equivalent to a total of around 156,000 people. As of today, no therapies are authorised in the EU for the treatment of IH. Patients with IH usually receive advice on lifestyle changes to help regulate their sleeping pattern. NLS' Mazindol ER is an alternative therapeutic option that has been historically used to treat a number of conditions. It is undergoing clinical trials in narcolepsy and other sleep disorders. This NPP will allow physicians to prescribe Mazindol ER off-label for use in treating IH.

On November 2, 2022, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for Mazindol ER for the treatment of IH. Previously, Mazindol ER was granted ODD for IH in Europe on July 21, 2022.

About NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd. is a Swiss clinical-stage biopharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex central nervous system disorders. The Company's lead product candidate, Quilience®, is a proprietary extended-release formulation of Mazindol (Mazindol ER) and is being developed for the treatment of narcolepsy, and potentially other sleep-wake disorders such as IH, for which NLS recently obtained ODD from the FDA and the European Medicines Agency (EMA). Mazindol is a triple monoamine reuptake inhibitor and partial Orexin-2 Receptor agonist, which was used for many years to treat patients diagnosed with narcolepsy in compassionate use programs. A Phase 2 multi-center U.S. clinical trial evaluating Quilience in adult subjects suffering from narcolepsy met its primary endpoint with high statistical significance and demonstrated a favorable safety and tolerability profile. NLS also successfully completed a Phase 2 study in the U.S. evaluating Nolazol (Mazindol Controlled-Release) in adult subjects suffering from ADHD. The study met all primary and secondary endpoints and Nolazol was well-tolerated. Quilience has received ODDs both in the U.S. and in Europe for the treatment of narcolepsy. Up to 1/3 of narcoleptic patients are also diagnosed with ADHD.

Safe Harbor Statement
This press release contains expressed or implied forward-looking statements pursuant to U.S. federal securities laws. For example, NLS is using forward-looking statements when it discusses that the NNP for IH is expected to expand into other countries and that physicians will be allowed to prescribe Mazindol ER off-label for use in treating IH. These forward-looking statements and their implications are based on the current expectations of the management of NLS only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; NLS may encounter delays or obstacles in launching and/or successfully completing its clinical trials; NLS' products may not be approved by regulatory agencies, NLS' technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; NLS may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with NLS' process; NLS' products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; NLS' patents may not be sufficient; NLS' products may harm recipients; changes in legislation may adversely impact NLS; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of NLS to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, NLS undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting NLS is contained under the heading "Risk Factors" in NLS' annual report on Form 20-F for the year ended December 31, 2021 filed with the U.S. Securities and Exchange Commission (SEC), which is available on the SEC's website, www.sec.gov, and in subsequent filings made by NLS with the SEC.

For more information on how physicians can access the NPP, please contact mazindolER@calcog.com and request further information to participate in this program.

Corporate Contact
Alex Zwyer, CEO: +41 44 512 21 50

Investor Relations Contact
Cindy Rizzo
invest@nls-pharma.com
www.nlspharmaceutics.com

SOURCE: NLS Pharmaceutics AG



View source version on accesswire.com:
https://www.accesswire.com/727870/NLS-Pharmaceutics-Announces-Launch-of-Paid-for-Named-Patient-Program-with-Mazindol-ER-for-Idiopathic-Hypersomnia-a-Serious-Sleep-Disorder-with-No-Approved-Treatment-Options-in-Europe

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Fortune 500 Leaders Share AI-powered Supply Chain Excellence on Stage at OMP Conference22.10.2025 11:00:00 CEST | Press release

Industry giants, including AstraZeneca, Johnson & Johnson, General Mills, and Kraft Heinz, to present real-world case studies in Miami MIAMI, FL / ACCESS Newswire / October 22, 2025 / OMP, a global leader in supply chain planning solutions, announced its lineup of customer speakers for the OMP REAL Conference 2025, taking place November 18-19 in Miami. The event will gather industry leaders, technology innovators, and supply chain experts to share how AI-powered supply chain planning delivers real business results. Speakers include executives from world-leading organizations, including Arxada,AstraZeneca, Beiersdorf, Eastman, Johnson & Johnson, Kraft Heinz, Land O'Lakes, and Visy. They will share real-world case studies of how they're leveraging OMP's Unison Planning™ to boost supply chain agility, resilience, and sustainability. Explore the program. Conference theme: REAL This year's theme - Real expertise. Real solutions. Real results. - underscores OMP's commitment to deliver tangib

Oman Hosts the Oman Investment Forum 2025 in the United Kingdom22.10.2025 08:00:00 CEST | Press release

Reform Metrics and Global Outlook Underpin London Gathering LONDON, UK, OM / ACCESS Newswire / October 22, 2025 / The Sultanate of Oman, represented by the Ministry of Finance in cooperation with the Ministry of Foreign Affairs, held the Oman Investment Forum 2025 in London to deepen financial, investment, and economic cooperation between the two nations. The event underscored the strategic weight of the Oman-UK partnership and the role of the Strategic Advisory Group (SAG), established in 2018 as the institutional mechanism through which the two countries coordinate investment, fiscal reform, and economic-diversification strategy. Oman enters this year's forum with one of the strongest fiscal positions in the region. Foreign Direct Investment (FDI) reached USD 78.8 billion by the end of the second quarter of 2025, a 12.8 percent increase compared to 2024. Inflows during the first half of 2025 totalled USD 8.8 billion, reflecting rising international confidence. Omani officials opened

Malaysia Expands Deployment of BlackBerry Secure Communications for the 46th and 47th ASEAN Summits22.10.2025 05:00:00 CEST | Press release

Malaysia modernizes mobile command and control, securing voice and messaging for inter-agency coordination with BlackBerry AtHoc and BlackBerry SecuSUITE KUALA LUMPUR, MY / ACCESS Newswire / October 21, 2025 / BlackBerry Limited (NYSE:BB)(TSX:BB) today announced that Malaysia has deployed BlackBerry® AtHoc® and BlackBerry® SecuSUITE® to secure communications and protect people during the ASEAN Summit events in 2025, including the 46th ASEAN Summit held in May, and the 47th ASEAN Summit taking place in Kuala Lumpur from October 26 to 28. The ASEAN Summits are among the region's most complex diplomatic events, involving more than 500 meetings and thousands of personnel across multiple government agencies. Coordinated by Malaysia's Ministry of Foreign Affairs through the ASEAN Main Logistics Secretariat (SILA), the Summits bring together heads of state, ministers, and officials from ASEAN member countries and key partners across the Americas, Europe, Africa, and Asia. Following a successf

FINOS Launches Fluxnova with Fidelity Investments, NatWest Group, Deutsche Bank and Capital One - An Open Source Orchestration Platform to Scale Process Automation21.10.2025 18:00:00 CEST | Press release

Announced at the Open Source in Finance Forum (OSFF), Fluxnova empowers financial institutions to modernize their infrastructure, reduce vendor dependency, and build long-term industry resilience. NEW YORK CITY, NY / ACCESS Newswire / October 21, 2025 / The Fintech Open Source Foundation (FINOS), the foundation of open innovation in financial services, today announced the launch of Fluxnova, an open orchestration platform developed in partnership with Fidelity Investments, NatWest Group, Deutsche Bank, and Capital One. Fluxnova delivers audit-ready workflows at scale, helping institutions visualize and automate their processes. By doing so, companies are better positioned to modernize operations and maintain strong governance across their processes. Fluxnova offers developers a toolkit for designing and deploying Business Process Model and Notation (BPMN) and Decision Model and Notation (DMN) models with a high-performance engine to execute and trace workflows. Business teams gain tran

Foundry Welcomes Gregory Anderson as Global Chief Revenue Officer21.10.2025 15:00:00 CEST | Press release

Global Sales Leader to Drive Unified Strategy and Accelerate Customer-Centric Growth NEW YORK CITY, NY / ACCESS Newswire / October 21, 2025 / Foundry, the leading global tech media, data, and marketing services company, is thrilled to announce the appointment of Gregory Anderson as Global Chief Revenue Officer (CRO). With two decades of proven success driving sales performance across technology and media sectors, Anderson joins Foundry with a clear focus on enhancing the buyer journey and accelerating strategic growth globally. Anderson joins Foundry from Informa TechTarget, where he most recently served as Chief Sales Officer at Omdia. During his tenure, he held several other key leadership roles, including positions leading sales and the integration of major acquisitions such as BrightTALK and Enterprise Strategy Group (ESG). He also spent eight years as VP of Sales for APAC at Informa TechTarget, where he helped expand regional operations. "We are thrilled to welcome Greg to the Fou

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye